

Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies

NCT07214688

Status	RECRUITING
Phase	Phase 2
Sponsor	Hackensack Meridian Health
Enrollment	209 participants

Key Eligibility Criteria

Inclusion (24)

- Patients ages 18-65 years.
 - Patients with a diagnosis of one of the following hematologic malignancies:
 - Acute myeloid leukemia or chronic myeloid leukemia with no circulating blasts and less than 5% blasts in the bone marrow;
 - Myelodysplastic syndrome with less than 5% blasts in the bone marrow by IHC or flow cytometry whichever is highest;
 - Myeloproliferative neoplasms with less than 5% blast in the marrow and peripheral blood;
- ... and 19 more (see full listing online)

Exclusion (6)

- Hematopoietic cell transplantation comorbidity index above 3.
 - Patients with a Karnofsky performance status (KPS) of $\leq 60\%$.
 - Patients with active infections or other contraindications for allogeneic stem cell transplant.
 - Patients who are unable or unwilling to give informed consent.
 - Patients who have received a prior allogeneic transplant.
- ... and 1 more (see full listing online)

Locations (3 total)

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington D.C., District of Columbia, United States

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

John Theurer Cancer Center at Jersey Shore University Medical Center, Neptune City, New Jersey, United States